1. Introduction {#s0005}
===============

Reciprocal translocations are one of the most common abnormalities in chromosomal structure, with an incidence of 1/500 to 1/625 human newborns ([@bb0090]). The origin of a reciprocal translocation is associated with inherited or de novo nonhomologous chromosome rearrangements, and exposure to chemicals and radiation ([@bb0140]). It has been reported that \> 6% of reciprocal carriers have a variety of symptoms, such as autism, intellectual disabilities, or congenital abnormalities ([@bb0040]). Most of them resulted from microdeletions, duplications, or gene disruption in carriers ([@bb0030], [@bb0105]). In addition, because of quadrivalent formations during meiosis, reciprocal translocation carriers with normal phenotype are likely to produce gametes with unbalanced products, which usually result in recurrent miscarriage and sometimes infertility. In these carriers, the genetic risk of reciprocal translocations should be carefully investigated.

A preimplantation genetic diagnosis (PGD) offers an effective treatment option for reciprocal translocation carriers to minimize the risk and distress of pregnancy loss caused by abnormal chromosomal segregation ([@bb0015]). Since the 1990s, fluorescence in situ hybridization (FISH) ([@bb0110]), array-based comparative genomic hybridization ([@bb0005]), and next-generation sequencing (NGS) ([@bb0130]) have been widely used in PGDs to detect abnormal copy numbers of chromosomal segments. In this scenario, both carrier and normal embryos had the same chance to be selected and result in live births and theoretically half of the offsprings will likely to inherit fertility problems. Furthermore, although reciprocal translocation do not increase the risk of physical or mental disability for most inherited balanced translocations ([@bb0035]), the breakpoint in de novo translocation carriers may interrupt functional genes which might generate harmful effects in later life.

To date, some approaches have been developed to distinguish normal and carrier embryos via PGD. Patient-specific breakpoint-spanning or closely flanking FISH probes could be designed to detect both numerical and structural aberrations in either interphase cells or in polar bodies for PGD ([@bb0085], [@bb0160]). Moreover, nuclear transferring of human blastomere into mature bovine or mouse oocytes could help to visualize metaphase chromosomes for full karyotyping in PGD ([@bb0150], [@bb0165]). However, patient-specific FISH probes design and optimization is time-consuming; and blastomere nuclei conversion needs both sophisticated embryologists for nuclei transfer and special cytogeneticists for single cell metaphase harvest and karyotyping in heterokaryons. More recently, it was reported that SNP array based comprehensive chromosome screening (CCS) was successfully used to distinguish normal from balanced translocation carrier embryos for most carrier couples ([@bb0135]). However, parental DNA and at least one unbalanced IVF embryo were necessary for the diagnosis, and the genetic risk of carrier cannot be evaluated since precise breakpoints were not identified. Currently there are no effective methods for all carrier couples to precisely identify breakpoints and/or linkage polymorphism markers for both carrier embryo diagnosis and genetic risk evaluation.

Breakpoint identification has been one of the most interesting fields in cytogenetics for investigating the phenotypic outcomes of reciprocal translocations. Several techniques had been developed to map chromosome breakpoints to the kilobase level ([@bb0020], [@bb0045], [@bb0055], [@bb0115], [@bb0120], [@bb0125], [@bb0145]). However, these techniques are time-consuming, expensive, and do not provide information about the breakpoint-linked SNPs for use in later PGDs. Recently, chromosome microdissection followed by NGS has been reported for use in precisely identifying the reciprocal translocation breakpoints at the level of the individual base in a leukemia patient ([@bb0070]). Here, we describe the "MicroSeq-PGD" method, which combines previously reported chromosome microdissection technique ([@bb0065]) and NGS followed by PGD, to characterize the DNA sequence of the translocation breakpoint and to distinguish between normal and carrier embryos in 8 reciprocal translocation carriers ([Fig. 1](#f0005){ref-type="fig"}).

2. Materials and Methods {#s0010}
========================

2.1. Study Patients {#s0015}
-------------------

This clinical diagnostic study was reviewed and approved by the Institutional Review Board (IRB) of the Reproductive and Genetic Hospital of CITIC-Xiangya (LL-SC-SG-2014-013). Metaphase spreads, DNA samples and whole genome amplification products of the patients were used for breakpoint analyses and further PGD. The study was conducted in compliance with the provisions of the Declaration of Helsinki. All patients provided written informed consent before diagnosis. This study included a total of 8 couples at the CITIC-Xiangya Hospital from July 1, 2014 to December 31, 2015. Either member of the couple had reciprocal translocations (excluding Robertsonian translocations, where the breakpoint is adjacent to the centromere). The karyotypes of the couples were determined from G-banded metaphase spreads obtained from peripheral blood using standard techniques.

2.2. Chromosome Microdissection {#s0020}
-------------------------------

Chromosome microdissection and PCR amplification of the microdissected DNA were performed as described previously ([@bb0060]). Five to eight copies of the region covering the breakpoints were dissected from G-banding metaphase spreads of the patients\' peripheral blood samples with glass needles. The dissected DNA fragments were amplified by DOP-PCR with UN1 primer (CCGACTCGAGNNNNNNATGTGG). An initial 6 cycles of PCR (denaturation at 94 °C for 1 min, annealing at 30 °C for 2 min, and extension at 37 °C for 2 min) were performed by adding 0.3 units of T7 DNA polymerase (Sequenase Version 2.0, USB, Cleveland, OH) at each cycle. A conventional PCR using Taq DNA polymerase was then performed for 35 cycles (denaturation at 94 °C for 1 min, annealing at 56 °C for 1 min, and extension at 72 °C for 2 min). Amplified DNA was labeled with spectrum-green or spectrum-red dUTP (Vysis, Downers Grove, IL) via PCR and then hybridized to metaphases from patients to confirm the success of chromosome microdissection.

2.3. Next Generation Sequencing of DNA from Microdissected Chromosomes {#s0025}
----------------------------------------------------------------------

Breakpoint mapping was based on parallel sequencing with a paired-end protocol and a bioinformatic analysis using the Integrative Genomics Viewer ([@bb0100]). Briefly, 100 ng of amplified microdissected DNA were fragmented by enzyme digestion and purified to yield fragments of 100--500 bp. P1 adaptor oligonucleotides from Life Tech were ligated on repaired A tailed fragments. About 150--300 bp fragments were separated, purified and enriched by electrophoresis and PCR cycles. Genomic libraries were prepared using the Ion Xpress library kit (Life Technologies Inc., Rockville, MD). Each DNA library was then sequenced on a Life Tech. Ion Proton system with 318 chips as paired-end 200-bp reads. Image analysis and base calling was performed using a Life Tech. 460 Flow system.

Sequence data were cleaned by removing the primer sequences and then were aligned to the reference genome (hg19) using the Integrative Genomics Viewer. Briefly, those sequences that could not be aligned to hg19 or aligned to multiple sites of hg19 were removed. SNPs were compared with dbSNP and 1000 Genomes Project database (<http://www.1000genomes.org>). The SNPs with a mutation frequency of \< 40% were picked as candidate breakpoint-specific SNPs. The cleaned sequence data were then aligned to hg19 with integrative genomics viewer.

2.4. Precise Characterization of Breakpoints {#s0030}
--------------------------------------------

We then synthesized specific primers that were supposed to be near to the breakpoints to amplify the junction fragments with genomic DNA from the translocation carriers. The PCR products were then sequenced to precisely identify the accurate breakpoints by Sanger sequencing.

We also synthesized specific primers to amplify and then sequenced the selected SNPs of the couples. Only the SNPs that were heterozygous in the translocation carriers and homozygous in their normal partner were considered as informative SNPs.

2.5. Comprehensive Chromosomal Screening {#s0035}
----------------------------------------

Preimplantation genetic diagnosis by comprehensive chromosomal screening was performed as previously described ([@bb0130]). Briefly, pituitary desensitization was performed using a long luteal Gonadotropin-releasing hormone (GnRH) agonist protocol based on patient situations ([@bb0025]). After oocyte retrieval, all eggs were fertilized by intracytoplasmic sperm injection (ICSI). All embryos were cultured in sequential media (G1 and G2, Vitrolife, Goteborg, Sweden) to the blastocyst stage. Approximately 3--8 trophectoderm (TE) cells were aspirated using a biopsy pipette with a 30-μm internal diameter and dissected with a Zilos TK laser (Hamilton Thorne, MA, USA). Biopsied TE cells were then used for whole genome amplification (WGA) via multiple displacement amplification with a REPLI-g Single Cell Kit (Qiagen, Valencia, CA). NGS and comprehensive chromosomal screening was then performed as previously described ([@bb0130]).

2.6. Carrier Embryo Diagnosis {#s0040}
-----------------------------

The excess WGA products were amplified with junction-spanning-specific primers via PCR, with genomic DNA of translocation carriers serving as the positive control and genomic DNA from healthy donors serving as the negative control. The informative SNPs flanking the breakpoint were amplified via PCR and then sequenced to reduce the risk of recombination. In the normal/carrier embryos diagnosed via PGD-CCS, only the embryos that were identified as positive in the junction-spanning PCR analysis and/or those positive for informative SNPs were predicted to be carrier embryos. The embryos that were negative in the junction-spanning PCR analyses and/or for informative SNPs were predicted to be normal embryos ([Fig. 1](#f0005){ref-type="fig"}).

2.7. Blastocyst Vitrification, Warming and Transfer {#s0045}
---------------------------------------------------

Blastocysts were vitrified after the biopsy using Kitazato vitrification solution (Kitazato Biopharma Co. Ltd. Shizuoka. Japan) and closed High Security Vitrification straws (Cryo Bio System, France). Each blastocyst was stored in an individual straw. After warming and dilution, blastocysts were cultured in blastocyst medium for 1--2 h. Only chromosomally normal/balanced blastocysts were selected for warming, and the surviving re-expanded blastocysts with high morphological grades were selected for transfer. Luteal support was applied in cryopreserved embryo transfer (CET) cycles. Warmed blastocysts were transferred either 5 days after ovulation during a natural menstrual cycle or 5 days after the initiation of ovulation via progesterone administration. Briefly, 6 mg Estradiol Valerate was started from Day 3 for 10--15 days, then luteal support was applied when a satisfactory endometrial development (thickness ≥ 8 mm) was confirmed with ultrasound. No more than two blastocysts were transferred, and single blastocyst transfer to each patient with well-cryopreserved embryos was recommended.

2.8. Prenatal Diagnosis {#s0050}
-----------------------

Clinical pregnancy was confirmed when an intrauterine gestational sac with a heartbeat was observed via ultrasound examination 30--40 days after embryo transfer. Amniocentesis was performed at 16--18 weeks\' gestation age. The amniocentesis fluid samples from fetuses were used for karyotyping to confirm the PGD results.

3. Results {#s0055}
==========

3.1. MicroSeq Analysis {#s0060}
----------------------

Totally 16 breakpoints for 8 translocation carriers were characterized. Reverse FISH using amplified DNA fragment as probes showed that all microdissected products covered rearrangement breakpoints ([Fig. 2](#f0010){ref-type="fig"}). The 16 amplified DNA samples were then sequenced at 1.76--3.59 million reads. We found that 17.3--56.4% of the reads were uniquely aligned to the reference human genome (hg19). The coverage of aligned reads to the dissected regions ranged from 3.6--35.7%. After mapping the same chromosomal sequences from two derivative chromosomes together, the breakpoints of each chromosomal translocation were narrowed down to 24 bp-8.96 kbp ([Table 1](#t0005){ref-type="table"}).

3.2. Breakpoint Characterization {#s0065}
--------------------------------

To further characterize the precise sequence of the rearrangement breakpoints, multiple PCR reactions spanning the narrowed-down regions of the derivative chromosomes were performed, and the amplicons were then sequenced to precisely identify the breakpoint sequences at the level of individual bases. We successfully identified 14 breakpoints in 7 patients. Interestingly, translocations in 6/7 patients caused the disruption of 9 genes, including the disease-related genes OLR1 and MERTK ([Table 1](#t0005){ref-type="table"}). Fortunately, further sequencing revealed that no mutation was detected in these 9 genes of their healthy spouses. Most breakpoints were in introns and had microhomologous sequences, deletions or insertions after the rearrangement ([Fig. S1](#f0020){ref-type="graphic"}). For case 6, with the t(6;22) translocation, the sequence from der(6) and der(22) that mapped to the reference genome of chromosome 6p12.1 had a 1086 bp gap (55,492,412--55,493,498) after alignment. However, the aligned sequence in 22q11.21 was located just inside a complex palindromic region, which resulted in an overlap of 103,267 bp (20,626,224--20,729,491) and a failure of junction-spanning PCR ([Fig. S2](#f0025){ref-type="graphic"}). Thus, the precise breakpoint in this patient could not be identified.

3.3. Breakpoint Adjacent SNPs Characterization {#s0070}
----------------------------------------------

From the sequence information obtained for the flanking rearrangement breakpoints, we identified 12,564 mutant SNPs in 8 patients, with 8--1453 SNPs per junction fragment ([Table 1](#t0005){ref-type="table"}). We selected 244 SNPs within 10 Mbp from the breakpoint and with a frequency of \< 40% in the 1000 Genomes Project database as candidate SNPs for the linkage analysis. The genotypes of selected SNPs in the balanced translocation carriers and their spouses were further analyzed via sequencing. Among them, we found that 124 SNPs were heterogeneous in the translocation carriers and homogenous in their spouses, which means that these were informative SNPs. With these SNPs, we successfully established partial haplotypes near the breakpoints of the derivative chromosomes in all 8 couples, with 2--17 SNPs per derivative chromosome ([Table S1](#ec0005){ref-type="supplementary-material"}).

3.4. Preimplantation Genetic Diagnosis {#s0075}
--------------------------------------

The 8 couples recruited in this study received 10 PGD treatment cycles. A total of 45 blastocysts were biopsied for WGA. Biopsy TE cells from 44 blastocysts were successfully amplified. After comprehensive chromosome screening via NGS, 26 out of the 44 blastocysts had translocation-related abnormalities, 3 blastocysts showed de novo aneuploidy unrelated to translocation, and the other 15 blastocysts were balanced, indicating that they were either normal or had balanced translocation ([Table S2](#ec0010){ref-type="supplementary-material"}).

We then performed a PCR analysis that spanned the breakpoints, and we amplified the breakpoint-adjacent informative SNPs for sequencing analysis with the rest of the WGA products to distinguish normal blastocysts from blastocysts with balanced translocations. In total, 124 SNPs within 10 Mbp of the rearrangement breakpoints were successfully analyzed. We then performed linkage analysis with the informative SNPs in 44 embryos of 8 patients. The total effective detection frequency is 593. Interestingly, recombinations were only observed at distances \> 5 Mbp from the breakpoint, from 0% (0/305) at \< 5 Mbp region to 4.45% (13/288) at \> 5 Mbp region ([Table S3](#ec0015){ref-type="supplementary-material"}). Thus, informative SNPs within 5 Mbp could be probably used to diagnose carrier embryos. The linkage analysis showed that 13 blastocysts were balanced translocation carriers, and only 2 blastocysts were normal ([Table S1](#ec0005){ref-type="supplementary-material"}, [Table S2](#ec0010){ref-type="supplementary-material"}). A junction-spanning PCR analysis was performed on 12 blastocysts from 7 patients whose rearrangement breakpoints had been successfully identified. Breakpoints were detected in 10 blastocysts, indicating that they were carrier embryos. The other two embryos were negative, indicating normal embryos. The junction-spanning PCR results showed 100% agreement with the previous linkage analysis results.

3.5. Clinical Outcome {#s0080}
---------------------

Before completing the analysis, 7 patients had already had their frozen embryos transferred. Nine blastocysts were thawed, and 8 blastocysts survived. Seven transfer cycles were performed, and 4 women became pregnant. In one woman, the pregnancy ended at 45 days after the embryo transfer (ET) in her first cycle, but she successfully became pregnant at the second ET. After prenatal diagnosis via amniocentesis, all of the babies were diagnosed as balanced translocation carriers. To date, five healthy babies with balanced translocation have been successfully delivered. These results agree with previous predictions ([Table S2](#ec0010){ref-type="supplementary-material"}). For case 8, the carrier analysis results came out before her frozen embryo was transferred. She had 4 balanced blastocysts: three blastocysts were predicted to be carrier embryos and only one to be normal. After giving informed consent, the patient decided to have the normal blastocyst transferred, and a successful pregnancy was established. A prenatal diagnosis confirmed that the fetus had a normal karyotype ([Fig. 3](#f0015){ref-type="fig"}). Furthermore, for all 29 chromosomal unbalanced embryos, existence of derivative chromosomes predicted by junction-spanning PCR and/or breakpoint-adjacent informative SNPs analysis was consistent with that was predicted by PGD-CCS ([Table S2](#ec0010){ref-type="supplementary-material"}). The above results also proved the accuracy of our PGD approach based on MicroSeq technique.

4. Discussion {#s0085}
=============

PGD is currently used to exclude chromosomally unbalanced embryos and to ensure a successful live birth for balanced translocation carriers with an unfortunate obstetric history or infertility. Although a variety of techniques have been developed to identify carrier embryos in PGD, the efficiency and consistence performance of these techniques between individuals hampered their clinical applications. In this scenario, embryos with normal karyotypes from translocation carriers cannot be preferentially transferred and one half of the offsprings would theoretically inherit the translocation-bearing chromosomes and may face reproductive difficulties in the future. Moreover, the genetic risk caused by de novo reciprocal translocation was not investigated routinely in phenotypically normal carriers. In the current study, using MicroSeq approach, we were generally able to precisely map rearrangement breakpoints to the level of individual bases. Compare with other available techniques, this approach combines chromosome microdissection and NGS techniques. Precise dissection of chromatin covering breakpoint minimizes the following NGS cost. NGS of amplified dissected DNA can reliably and accurately obtain sequence of junction fragments, which help to precisely identify the breakpoint as well as nearby SNPs. It takes only 5 days for chromosome microdissection, and regular library construction protocol is suitable for the following NGS.

In most cases, we found that multiple genes were disrupted and that some potential pathogenic genes were affected by balanced translocations. Although most interrupted genes in this study are recessive, balanced translocation offsprings may suffer from genetic defects if another allele had pathogenic mutations or deletions. In the 9 disrupted genes from the 8 patients, homozygous loss of function of Acly, DDX60, Fkh5 and Aldh1a1 were associated with lethal in early embryo development ([@bb0010]),defects in antiviral immune response ([@bb0095]), severe growth retardation ([@bb0155]) and sensitivity for retinol toxicity ([@bb0080]) respectively. Moreover, MERTK, a recessive gene that had been associated with retinal dystrophy ([@bb0075]), was disrupted in another patient. Fortunately, in the follow-up study there was no genetic mutation detected in those disrupted genes in the healthy spouse genome. Taking the above observations into consideration, although no discernible increased risk of clinical abnormality was observed in the children with the same balanced translocation karyotype as in their asymptomatic carrier parents ([@bb0035]), our data suggest that potential genetic risks may exist in phenotypically normal de novo translocation carriers. Considering the risks of further reproductive difficulties and the potential genetic risks, it is worthy to characterize and evaluate the breakpoint-affected genes ahead. Nevertheless, the significance of gene interruption should be evaluated and consulted by professional genetic consultants, especially regarding genes of unknown significance and cancer predisposition genes.

In this study, we observed a bias of carrier to non-carrier embryos with a ratio of 13:2. However, limited sample size may account for this bias. Treff and colleagues evaluated 126 balanced embryos in PGD by SNP array based CCS. Among them, 62 (49%) were predicted to be normal embryos and 64 (51%) were predicted as balanced translocation carrier embryos ([@bb0135]). Thus, more data and appropriate statistical methods are needed to measure the carrier to non-carrier embryo ratio. Moreover, it is important to inform that a non-carrier embryo is no guarantee in any one PGD cycle, and a carrier embryo could also be transferred if no further genetic risk is detected.

In this study, the number of informative SNPs was highly viable from breakpoint to breakpoint. The amplification efficiency of DOP-PCR may account for this variation. However, there are enough informative SNPs for further PGD for embryos with balanced translocations. Moreover, we only included the SNPs with \> 10 × coverage in this study. Since more informative SNPs will minimize the impact of allelic dropout to ensure the PGD accuracy, SNPs with \< 10 × coverage could also be tested and included to increase the number of SNPs for further PGD. For Robertsonian translocations, although it is difficult to find exact breakpoints that located in cetromeric region, nearby informative SNPs linkage analysis will help to discriminate normal embryos and embryos with balanced Robertsonian translocations. However, the position of informative SNPs should be carefully investigated to avoid recombination-caused misdiagnosis.

Although the breakpoints in 22q11.21 in one patient were not identified due to interference from complex palindromic sequences, we successfully characterized the SNPs adjacent to the rearrangement breakpoints in all patients. The guidelines of the European Society of Human Reproduction and Embryology suggest that extragenic markers within 1 Mbp of a mutation should be included in PGDs to reduce mistakes caused by recombination, as the probability for recombination within 1 Mbp is low ([@bb0050]). However, according to our linkage analysis, data from 44 embryos from reciprocal carriers show that recombination events were not observed within 5 Mbp of the rearrangement breakpoint. It is possible that the increased distance of the homologous chromatids in the center of the quadrivalent reduced the chances of recombination in the flanking sequences of the rearrangement breakpoints. This finding enabled us to obtain more informative SNPs over a relatively wider area for use in PGDs. This also makes a less-detailed MicroSeq sequencing step practical.

In this study, we succeeded in developing a reliable approach for performing linkage and junction-spanning PCR analyses to distinguish normal and carrier embryos in a PGD based on the information provided by a MicroSeq analysis. This approach has been shown to be effective based on the prenatal validation of the initial diagnoses. However, the sensitivity and specificity of this approach should be evaluated in a larger sample size. In addition, this approach may also provide a future means of diagnosing embryos that are carriers of Robertsonian translocations and inversions during PGDs.

The following are the supplementary data related to this article.Fig. S1Junction fragment sequences of the seven cases whose breakpoints were identified.Sequences from two chromosomes are labeled in blue or purple. Arrows show the direction. Deleted sequences are shown in green. Inserted sequences are marked with red and in lower case. Micro-homologies are indicated in bold capital characters. (Chr) chromosome, (der) derivative chromosome.Fig. S1Fig. S2Alignment results of NGS sequences from der(6) and der(22) in case 6.The sequence from der(6) to der(22) that mapped to the reference genome of chromosome 6 had a 1086 bp gap (55, 492, 412--55, 493, 498) after alignment (a). However, the aligned sequence in 22q11.21 had an overlap of 103.267 kb (20, 626, 224--20, 729, 491) (b).Fig. S2Table S1Summary of breakpoint ajacent informative SNPs and PGD results of the eight patients and their embryos.Table S1Table S2Summary of the PGD results for all embryos of the eight patients.Table S2Table S3Summary of breakpoint ajacent informative SNPs linkage analysis in 44 embryos.Table S3
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![Discrimination of normal and carrier embryos via MicroSeq and PGD.\
Junction fragments of derivative chromosomes were microdissected and amplified via DOP-PCR. The amplified DNA samples were sequenced using next generation sequencing. Precise breakpoints were determined via long-range PCR. Informative breakpoint-linked SNPs were identified in a bioinformatics analysis and confirmed by sequencing the selected SNPs in the couples. In the normal/carrier embryos diagnosed via PGD-CCS, only the embryos that were identified as positive in the junction-spanning PCR analysis and/or those positive for informative SNPs were predicted to be carrier embryos. The embryos that were negative in the breakpoint and junction-spanning PCR analyses and/or for informative SNPs were predicted to be normal embryos.](gr1){#f0005}

![Reverse FISH of microdissected DNA.\
Reciprocal translocations of the eight patients are illustrated in the upper panel. Reverse FISH using amplified DNA fragment as probes shows that all microdissected products cover rearrangement breakpoints (lower panel).](gr2){#f0010}

![PGD and carrier diagnosis of a t(9;17) patient.\
In total, 7 embryos were obtained and analyzed. Based on complete chromosome screening, embryos 1, 2, 4, and 7 were identified as normal/carrier embryos, whereas embryos 3, 5, and 6 were identified as unbalanced embryos (a). Junction-spanning PCR analysis of whole-genome amplification products from embryos showed that embryos 1, 4, and 7 were positive and that embryo 2 was negative (b), indicating that only embryo 2 was a normal embryo, while the other 3 embryos were carriers. SNP analysis confirmed that only embryo 2 was negative for informative SNPs (red) characters in panel (c). The normal blastocyst was transferred after the subject gave informed consent, and a successful pregnancy was established. Prenatal diagnosis confirmed that the fetus had a normal karyotype (d).](gr3){#f0015}

###### 

Summary of breakpoint characterization results of the eight patients

Table 1

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   Carrier karyotype[a](#tf0005){ref-type="table-fn"}   der       chr     No. of mapped sequencing reads   Coverage\   Distance of the nearest NGS mapping reads to breakpoint (bp)   Total_Mutation SNP numbers     Identifying linked to breakpoint informative SNPs number   Breakpoint position from Sanger sequencing   Disrupt gene (break region)                                                                                                                       OMIM ID   Gene Ontology
                                                                                                                    (%)                                                                                                                                                                                                                                                                                                                                                                           
  --------- ---------------------------------------------------- --------- ------- -------------------------------- ----------- -------------------------------------------------------------- ------------------------------ ---------------------------------------------------------- -------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- --------- ---------------------------------------------
  1         46,XX,t(4;17)(q32.3;q21.2)                           der(4)    4       50,516                           3.59        2,347                                                          58                             2                                                          chr4:169,227,027-169,227,031                 DDX60 (Intron 5/37)                                                                                                                               613974    Nucleic acid binding and hydrolase activity

  17        167,018                                              5.41      3,506   74                               0                                                                                                                                                                                                                                                                                                                                                                             

  der(17)   4                                                    34,792    6.35    1,514                            43          6                                                              chr17:40,053,060-4,005,3061    ACLY (Intron 13/28)                                        108728                                       Cofactor binding and ATP citrate synthase activity                                                                                                          

  17        81,784                                               10.45     2,258   31                               4                                                                                                                                                                                                                                                                                                                                                                             

  2         46,XY,t(3;12)(q25.2;p13.2),inv(9)(p11q13)            der(3)    3       169,432                          9.89        818                                                            428                            3                                                          chr3:153,121,850-153,121,851                 --                                                                                                                                                --        --

  12        175,243                                              19.14     614     328                              7                                                                                                                                                                                                                                                                                                                                                                             

  der(12)   3                                                    349,210   12.12   1,144                            130         0                                                              chr12:10,311,870-10,311,877    OLR1 (Exon 4/4)                                            602601                                       Carbohydrate binding and low-density lipoprotein receptor activity                                                                                          

  12        206,640                                              20.02     1,177   100                              0                                                                                                                                                                                                                                                                                                                                                                             

  3         46,XX,t(4;15)(q23;q22.2)                             der(4)    4       156,036                          9.66        898                                                            149                            2                                                          chr4:100,891,783-100,891,784                 --                                                                                                                                                --        --

  15        215,786                                              9.23      206     176                              4                                                                                                                                                                                                                                                                                                                                                                             

  der(15)   4                                                    440,532   9.27    561                              517         3                                                              chr15:60,310,881-60,310,896    FOXB1 (Intron 1/2)                                         --                                           Transcription factor activity, sequence-specific DNA binding and RNA polymerase II transcription factor activity, sequence-specific DNA binding             

  15        241,418                                              10.21     1,045   186                              5                                                                                                                                                                                                                                                                                                                                                                             

  4         46,XX,t(1;2)(p31.1;q13)                              der(1)    1       735,087                          23.73       223                                                            87                             1                                                          chr1:70,936,280-70,936,290                   --                                                                                                                                                --        --

  2         203,356                                              16.74     2,045   162                              3                                                                                                                                                                                                                                                                                                                                                                             

  der(2)    1                                                    183,725   14.14   167                              1,214       8                                                              chr2:112,661,491-112,661,518   MERTK (Intron 1/18)                                        604705                                       Transferase activity, transferring phosphorus-containing groups and protein tyrosine kinase activity                                                        

  2         158,214                                              18.75     1,362   358                              5                                                                                                                                                                                                                                                                                                                                                                             

  5         46,XY,t(8;20)(p21.3;q13.33)                          der(8)    8       215,633                          30.18       250                                                            161                            7                                                          chr8:22,991,894-22,991,895                   --                                                                                                                                                --        --

  20        11,242                                               26.68     0       8                                0                                                                                                                                                                                                                                                                                                                                                                             

  der(20)   8                                                    189,386   15.74   2,210                            223         4                                                              chr20:61,754,133-61,754,134    --                                                         --                                           --                                                                                                                                                          

  20        310,178                                              18.2      6,750   518                              7                                                                                                                                                                                                                                                                                                                                                                             

  6         46,XY,t(6;22)(p12.1;q11.21)                          der(6)    6       36,694                           24.12       NA                                                             57                             0                                                          --                                           --                                                                                                                                                --        --

  22        89,584                                               10.4      NA      50                               2                                                                                                                                                                                                                                                                                                                                                                             

  der(22)   6                                                    675,112   29.86   NA                               1,194       3                                                              --                             --                                                         --                                           --                                                                                                                                                          

  22        101,853                                              22.44     NA      183                              2                                                                                                                                                                                                                                                                                                                                                                             

  7         46,XX,t(4;9)(q21.23;q21.13)                          der(4)    4       572,409                          35.73       0                                                              856                            9                                                          chr4:84,877,905-84,877,912                   BC005018 (Intron 7/7)                                                                                                                             --        NA

  9         550,854                                              31.51     24      1,236                            8                                                                                                                                                                                                                                                                                                                                                                             

  der(9)    4                                                    555,651   16.84   302                              1,072       8                                                              chr9:75,640,607-75,640,608     ALDH1A1 (Intron 1/12)                                      100640                                       Oxidoreductase activity and acyl-CoA dehydrogenase activity                                                                                                 

  9         76,442                                               25.86     121     160                              4                                                                                                                                                                                                                                                                                                                                                                             

  8         46,XY,t(9;17)(q31.3;q25.3)                           der(9)    9       152,030                          6.1         880                                                            102                            2                                                          chr9:114,402,958-114,402,959                 DNAJC25 (Intron 1/4)                                                                                                                              --        Signal transducer activity

  17        27,428                                               5.74      925     15                               0                                                                                                                                                                                                                                                                                                                                                                             

  der(17)   9                                                    590,926   32.54   1,490                            1,235       7                                                              chr17:76,740,337-76,740,338    CYTH1 (Intron 1/12)                                        182115                                       Lipid binding and ARF guanyl-nucleotide exchange factor activity                                                                                            

  17        898,244                                              31.53     160     1,453                            8                                                                                                                                                                                                                                                                                                                                                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Carrier karyotypes in this table have been revised following the breakpoint mapping information and the original G-band karyotypes are provided in [Table S2](#ec0010){ref-type="supplementary-material"}.

[^1]: These authors contributed equally to this work.
